Moleac
Singapore, Singapore· Est.
Moleac commercializes evidence‑based herbal medicines for stroke, TBI and neurodegeneration, with NeuroAiD already generating global sales.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Moleac commercializes evidence‑based herbal medicines for stroke, TBI and neurodegeneration, with NeuroAiD already generating global sales.
NeurologyStrokeTraumatic Brain InjurySpinal Cord InjuryAlzheimer's Disease
Technology Platform
Standardized, evidence‑based herbal formulations that target endogenous brain repair pathways, delivered as oral adjunct therapies.
Opportunities
Expansion of NeuroAiD into Alzheimer’s disease and other cognitive disorders, regulatory approval of MLC1501, and deeper market penetration in Asia and the Middle East.
Risk Factors
Regulatory hurdles for herbal products, need for large‑scale efficacy data, and competition from synthetic neuro‑protective agents.
Competitive Landscape
Few competitors offer evidence‑based herbal post‑stroke therapies; Moleac differentiates through extensive clinical data, global distribution, and a multi‑indication pipeline.